Skip to Content

Vasopressin Pregnancy and Breastfeeding Warnings

Vasopressin is also known as: Pitressin, Vasostrict

Medically reviewed on Mar 20, 2017

Vasopressin Pregnancy Warnings

Animal studies have not been reported. Due to increased clearance of this drug in the second and third trimester, IV doses may need to be up-titrated to doses exceeding 0.1 units/min in post-cardiotomy shock and 0.07 units/min in septic shock. This drug may produce tonic uterine contractions that could threaten continuation of pregnancy. There are no controlled data in human pregnancy.

AU TGA pregnancy category B2: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended unless clearly needed.

AU TGA pregnancy category: B2
US FDA pregnancy category: C

See references

Vasopressin Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-No information is available on clinical use of this drug during breastfeeding, however, a derivative, desmopressin, results in only small increases in milk arginine vasopressin levels.
-Because this drug is not orally absorbed, it is unlikely to adversely affect a breastfed infant.
-Consider advising a breastfeeding woman to pump and discard breast milk for 1.5 hours after receiving this drug to minimize potential exposure.

See references

References for pregnancy information

  1. "Product Information. Vasopressin (vasopressin)." APP (Abraxis Pharmaceutical Products), Schaumberg, IL.
  2. "Product Information. Vasostrict (vasopressin)." Par Pharmaceutical Inc, Chestnut Ridge, NY.
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. "Product Information. Vasostrict (vasopressin)." Par Pharmaceutical Inc, Chestnut Ridge, NY.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  3. "Product Information. Vasopressin (vasopressin)." APP (Abraxis Pharmaceutical Products), Schaumberg, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide